When did OGN start trading?

The launch of Organon's regular-way trading on the NYSE is a testament to the company's readiness to operate independently and compete in the healthcare industry. It signals confidence in Organon's business model, growth prospects, and ability to deliver value to shareholders.

Organon, a newly spun-off company from Merck, is set to commence regular-way trading on the New York Stock Exchange (NYSE) on June 3, 2021. This marks a significant milestone in the company's journey as it embarks on its independent path.

The trading of Organon shares will commence under the ticker symbol "OGN," signifying the company's fresh start and unique identity in the market. Investors will now have the opportunity to trade Organon shares separately from Merck.

In addition to its focus on women's health, Organon also brings a wealth of experience and expertise in drug development and commercialization. This expertise, combined with its commitment to innovation and patient-centric care, positions the company well for success in the healthcare market.

Meanwhile, Merck, the parent company of Organon, will continue to trade on the NYSE under its existing ticker symbol "MRK." This ensures that Merck's operations and financial performance remain distinct from those of Organon.